Understanding the Mechanism of Mucosal Immunotherapy

了解粘膜免疫治疗的机制

基本信息

  • 批准号:
    7643975
  • 负责人:
  • 金额:
    $ 38.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-15 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Oral tolerance to foods normally develops during the first few years of life. An aberration of oral tolerance, food allergy, occurs in 6% of children and 3.5% of adults in the United States. Egg and peanut allergy are two of the most common food allergies occurring in 1.5% and 1% of young children, respectively. Interestingly, approximately 50% of young children with egg allergy then develop oral tolerance to egg by age 5 years, while only 20% of young children develop oral tolerance to peanuts by age 5 years. We propose to utilize a form of treatment, oral immunotherapy (OIT) to investigate and possibly hasten the development of oral tolerance to eggs and peanuts. This application is based on our data that allergen-specific OIT will desensitize and possibly tolerize egg-allergic and peanut-allergic subjects. Our hypothesis is that instituting egg and peanut OIT early after development of egg or peanut allergy will clinically desensitize both groups of patients by altering basophil/mast cell reactivity and will cause clinical tolerance to develop because of the activity of specific T regulatory cells for egg and peanut. This study will provide new insights into the natural history of the egg- and peanut-specific cellular and humoral immune responses and oral tolerance. This proposal is based on our preliminary studies that have examined the effects of OIT on egg and peanut allergies. Our approach will be to enroll two cohorts of subjects and controls early in life who have egg allergy or peanut allergy both soon after their development and treat them with either egg or peanut OIT in a randomized, blinded OIT protocol. Utilizing an already established protocol of study subjects entering a proof of concept study funded by the Food Allergy Project, we will study the basophil/mast cell reactivity, antigen-specific T cell responses and mucosal and systemic humoral immune responses in these subjects. This grant application is not intended to support the clinical trial portion of this work but only the mechanistic studies as described. Our specific aims are the following: (1) determine if the development of the desensitized state to egg and peanut is associated with the down-regulation of mast cells and basophils, (2) determine if the development of clinical tolerance to egg and peanuts is associated with an increase in the T regulatory phenotype of antigen-activated peripheral CD4+ T cells and (3) determine the effect of egg- and peanut-specific mucosal and systemic humoral immune responses on oral tolerance and OIT. The short-term goal of the protocol is to induce a desensitized state to egg and peanut early in the course of treatment that will protect subjects from allergic reactions following accidental egg or peanut ingestions. The long-term goal of the study is to utilize egg and peanut OIT for the induction of clinical and immunologic tolerance to the allergen that will be sustained once the protocol is completed.
描述(由申请人提供):对食物的口服耐受性通常在生命的头几年发展。在美国,有6%的儿童和3.5%的成年人发生口服耐受性,食物过敏。卵和花生过敏是分别以1.5%和1%的幼儿发生的两种最常见的食物过敏。 有趣的是,大约50%的卵过敏的幼儿在5岁时对卵产生口服耐受性,而只有20%的幼儿在5岁时会出现对花生的口服耐受性。我们建议利用一种治疗形式,口服免疫疗法(OIT)来调查并可能加快对卵和花生的口服耐受性的发展。该应用基于我们的数据,该数据是过敏原特异性OIT将脱敏并可能耐受卵过敏和花生过敏性受试者。我们的假设是,卵或花生过敏后早期提早建立卵和花生OIT将通过改变嗜碱性粒细胞/肥大细胞反应性来在临床上脱敏两组患者,并会导致临床耐受性,因为卵和花生的特定T调节细胞的活性。这项研究将提供有关卵和花生特异性细胞和体液免疫反应以及口服耐受性的自然历史的新见解。该提议基于我们的初步研究,该研究检查了OIT对卵和花生过敏的影响。我们的方法是在生命的早期招募两个受试者和对照组,他们在发育后不久就会接受卵过敏或花生过敏,并用随机的,盲目的OIT方案中的鸡蛋或花生OIT对其进行处理。利用已经建立的研究对象的方案,该方案进入了由食物过敏项目资助的概念验证研究,我们将研究这些受试者中的嗜碱性粒细胞/肥大细胞反应性,抗原特异性T细胞反应以及粘膜和全身性体液免疫反应。 该赠款的应用并非旨在支持这项工作的临床试验部分,而仅支持所述的机械研究。 Our specific aims are the following: (1) determine if the development of the desensitized state to egg and peanut is associated with the down-regulation of mast cells and basophils, (2) determine if the development of clinical tolerance to egg and peanuts is associated with an increase in the T regulatory phenotype of antigen-activated peripheral CD4+ T cells and (3) determine the effect of egg- and peanut-specific mucosal and口服耐受性和OIT的全身性体液免疫反应。 该方案的短期目标是在治疗过程的早期对卵和花生诱导脱敏状态,以保护受试者免受意外卵或花生摄入后的过敏反应。该研究的长期目标是利用鸡蛋和花生OIT来诱导一旦协议完成,对过敏原诱导了对过敏原的临床和免疫耐受性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

A. Wesley Burks其他文献

Intestinal Barrier Dysfunction Accompanies Peanut Allergy in CC027/GeniUnc Mice
  • DOI:
    10.1016/j.jaci.2020.12.616
  • 发表时间:
    2021-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Erin Steinbach;Johanna Smeekens;Layna Perini;Satyaki Roy;Ana Berglind;Michael Kulis;Martin Ferris;Terrence Furey;A. Wesley Burks;Shehzad Sheikh
  • 通讯作者:
    Shehzad Sheikh
Oral immunotherapy for food allergy: clinical and preclinical studies.
食物过敏的口服免疫疗法:临床和临床前研究。
Biomarkers for Desensitization in Patients Undergoing Sublingual Immunotherapy for Peanut Allergy
  • DOI:
    10.1016/j.jaci.2020.12.406
  • 发表时间:
    2021-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Suzanne Barshow;Barry Hurlburt;Jane McBride;Soheila Maleki;Ping Ye;Quefeng Li;A. Wesley Burks;Michael Kulis;Edwin Kim
  • 通讯作者:
    Edwin Kim
Exploiting CD22 on Memory B Cells to Induce Tolerance to Peanut Allergens
  • DOI:
    10.1016/j.jaci.2021.12.022
  • 发表时间:
    2022-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Lakeya Hardy;Johanna Smeekens;Gour Daskhan;Susmita Sarkar;Stephen Rogers;Soheila Maleki;A. Wesley Burks;James Paulson;Matthew Macauley;Michael Kulis
  • 通讯作者:
    Michael Kulis
Efficacy and Safety of AR101 in Peanut Allergy: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
  • DOI:
    10.1016/j.jaci.2017.12.941
  • 发表时间:
    2018-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Stacie M. Jones;Kirsten Beyer;A. Wesley Burks;Thomas B. Casale;Jonathan O'B. Hourihane;Annette Marcantonio;Andrea Vereda;Brian P. Vickery;Rezi Zawadzki;Daniel C. Adelman
  • 通讯作者:
    Daniel C. Adelman

A. Wesley Burks的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('A. Wesley Burks', 18)}}的其他基金

NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY
预防和治疗食物过敏的新视野
  • 批准号:
    9443585
  • 财政年份:
    2017
  • 资助金额:
    $ 38.26万
  • 项目类别:
NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY
预防和治疗食物过敏的新视野
  • 批准号:
    9889023
  • 财政年份:
    2017
  • 资助金额:
    $ 38.26万
  • 项目类别:
NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY
预防和治疗食物过敏的新视野
  • 批准号:
    10581628
  • 财政年份:
    2017
  • 资助金额:
    $ 38.26万
  • 项目类别:
NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY
预防和治疗食物过敏的新视野
  • 批准号:
    10631369
  • 财政年份:
    2017
  • 资助金额:
    $ 38.26万
  • 项目类别:
NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY
预防和治疗食物过敏的新视野
  • 批准号:
    10363631
  • 财政年份:
    2017
  • 资助金额:
    $ 38.26万
  • 项目类别:
NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY
预防和治疗食物过敏的新视野
  • 批准号:
    10398330
  • 财政年份:
    2017
  • 资助金额:
    $ 38.26万
  • 项目类别:
Combined Peanut Oral Immunotherapy and Anti-IgE: Mechanistic Studies
花生口服免疫疗法与抗 IgE 联合治疗:机制研究
  • 批准号:
    8449783
  • 财政年份:
    2011
  • 资助金额:
    $ 38.26万
  • 项目类别:
Combined Peanut Oral Immunotherapy and Anti-IgE: Mechanistic Studies
花生口服免疫疗法与抗 IgE 联合治疗:机制研究
  • 批准号:
    8094570
  • 财政年份:
    2011
  • 资助金额:
    $ 38.26万
  • 项目类别:
Combined Peanut Oral Immunotherapy and Anti-IgE: Mechanistic Studies
花生口服免疫疗法与抗 IgE 联合治疗:机制研究
  • 批准号:
    8320084
  • 财政年份:
    2011
  • 资助金额:
    $ 38.26万
  • 项目类别:
Sublingual Immunotherapy for Peanut Allergy
花生过敏的舌下免疫疗法
  • 批准号:
    7614511
  • 财政年份:
    2008
  • 资助金额:
    $ 38.26万
  • 项目类别:

相似国自然基金

成人型弥漫性胶质瘤患者语言功能可塑性研究
  • 批准号:
    82303926
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
  • 批准号:
    82302160
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
SMC4/FoxO3a介导的CD38+HLA-DR+CD8+T细胞增殖在成人斯蒂尔病MAS发病中的作用研究
  • 批准号:
    82302025
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
融合多源异构数据应用深度学习预测成人肺部感染病原体研究
  • 批准号:
    82302311
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Neonatal Optical Coherence Tomography Angiography to Assess the Effects of Postnatal Exposures on Retinal Development and Predict Neurodevelopmental Outcomes
新生儿光学相干断层扫描血管造影评估产后暴露对视网膜发育的影响并预测神经发育结果
  • 批准号:
    10588086
  • 财政年份:
    2023
  • 资助金额:
    $ 38.26万
  • 项目类别:
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 38.26万
  • 项目类别:
Identifying correlates of risk for future tuberculosis disease progression in children (INTREPID)
确定儿童未来结核病进展风险的相关性 (INTREPID)
  • 批准号:
    10637036
  • 财政年份:
    2023
  • 资助金额:
    $ 38.26万
  • 项目类别:
Effects of age of acquisition and of community on argument ordering
习得年龄和社区对论证顺序的影响
  • 批准号:
    10825319
  • 财政年份:
    2023
  • 资助金额:
    $ 38.26万
  • 项目类别:
More Outside Your Door (MOYD)
更多户外活动 (MOYD)
  • 批准号:
    10621538
  • 财政年份:
    2023
  • 资助金额:
    $ 38.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了